Topical anesthetics in dentistry: the dose limits that are printed, the ones that are not, and what a compounded tube does not tell you

What it says#

This entry reports what the manufacturers' labels say. The treating dentist decides what goes on the patient in the chair, and a stated maximum is a limit, not a target.

Benzocaine 20% gel, over the counter. The HurriCaine label from Beutlich is a Drug Facts panel, and what is striking is what it does not contain: there is no milligram maximum anywhere on it. The directions read, for adults and children 2 years of age and older, apply to the affected area, allow to remain in place at least 1 minute and then spit out, use up to 4 times daily or as directed by a dentist or doctor; children under 12 should be supervised; children under 2 do not use. It carries the methemoglobinemia warning in full, an allergy alert for "caine" anesthetics, and "do not use for teething." The instruction to spit out after a minute is the whole dose control, and it is worth reading twice, because in practice a hygienist applies a topical and the patient swallows.

Cetacaine, prescription, the one with real numbers. The Cetylite labels for the spray, liquid and gel share a formula of benzocaine 14.0%, butamben 2.0% and tetracaine hydrochloride 2.0%, in a water-soluble base with benzalkonium chloride 0.5% and cetyl dimethyl ethyl ammonium bromide 0.005%. The spray label says: "Cetacaine Spray should be applied for approximately one second or less for normal anesthesia. Only a limited quantity of Cetacaine is required for anesthesia. Spray in excess of two seconds is contraindicated. Each one-second spray contains an average of 200 mg of product, not including propellant." For the liquid: "Apply 200 mg liquid (approximately 0.2 mL) directly to tissue. Liquid in excess of 400 mg (approximately 0.4 mL) is contraindicated." For the gel: dispense 200 mg, which the label describes as "a bead approximately 1/4 to 1/2 inches long," and "dispensing a bead of gel in excess of 400 mg is contraindicated."

The label then tells you exactly what that means in drug: "Each 200 mg dose of Cetacaine (Spray or Liquid) contains 28 mg of benzocaine, 4 mg of butamben and 4 mg of tetracaine HCl." So the two-second contraindication, on the label's own numbers, sits at roughly 400 mg of product, or 56 mg of benzocaine, 8 mg of butamben and 8 mg of tetracaine HCl. Cetacaine has no established pediatric dosage, is not to be used in infants or children younger than 2 years, should have doses reduced in debilitated, elderly, acutely ill and very young patients, should not be applied to large areas of denuded or inflamed tissue, should not be given to patients known to have cholinesterase deficiencies, and "is not suitable and should never be used for injection."

Oraqix, the periodontal gel. Dentsply's Oraqix is lidocaine 25 mg/mL and prilocaine 25 mg/mL, supplied in cartridges that deliver 1.7 g of gel containing 42.5 mg of lidocaine and 42.5 mg of prilocaine. It is "indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing." The technique is specified to the second: apply on the gingival margin with the blunt-tipped applicator, wait 30 seconds, fill the periodontal pockets until the gel becomes visible at the margin, wait another 30 seconds, and start. A longer waiting time does not enhance the anesthesia. The anesthetic effect lasts approximately 20 minutes, with an individual overall range of 14 to 31 minutes, and typically one cartridge or less will be sufficient for one quadrant.

"The maximum recommended dose of Oraqix at one treatment session is 5 cartridges, i.e., 8.5g gel." At 42.5 mg per cartridge that is 212.5 mg of lidocaine and 212.5 mg of prilocaine, which is the figure the label itself uses in its pharmacokinetics section. The label also prints the consequence of that dose: plasma lidocaine ranged from 157 to 552 ng/mL with a mean of 284, prilocaine 53 to 181 ng/mL with a mean of 106, and blood methemoglobin rose from a baseline of 0 to 1.1% up to 0.8 to 1.7%, peaking 1 to 4 hours after. Two warnings matter chairside: "DO NOT INJECT," and Oraqix "should not be used with standard dental syringes," only with its own blunt-tipped applicator and dispenser. And the overdosage section says that if other local anesthetics are administered at the same time, topically or by injection, the toxic effects are thought to be additive and could result in an overdose. Safety and effectiveness in pediatric patients have not been established, and the label notes that very young children are more susceptible to methemoglobinemia, with reports of clinically significant methemoglobinemia in infants and children following excessive applications of lidocaine 2.5% topical cream.

Compounded topicals. The most useful thing to look at is an actual record. DailyMed carries a label for "Lidocaine USP 15% / Phenylephrine HCl USP 0.25% / Prilocaine USP 5%" ointment from Sincerus Florida, published May 17, 2019, with a marketing category of "unapproved drug other." The entire label content is a product name, an NDC, a 120 gram package size, and stub headings. There is no dose, no maximum, no warnings section, no contraindication and no methemoglobinemia language. Compare the concentrations: the approved periodontal gel is lidocaine 2.5% and prilocaine 2.5%, and this is lidocaine 15% and prilocaine 5%.

The FDA has published advisories about compounded topical anesthetics. This entry does not quote them, because fda.gov returned HTTP 401 to every automated request made in this session, and nothing is reported here that was not read.

Who it applies to#

Hygienists and assistants first, because they are the people who actually apply these products, and they are usually applying them without a dentist in the room. The numbers that govern topicals are not clinical judgments, they are counts and timings: one second, two seconds, one minute, five cartridges.

It applies to adults only for Oraqix, and to patients 2 years and older for the benzocaine and Cetacaine products. There is no approved dental topical in this entry with a pediatric dose established below 2 years.

It applies with particular force to the patient who gets a topical and then an injection, which is nearly every restorative patient. The Oraqix label is the one that says out loud what the others imply: the toxic effects of concurrent local anesthetics are thought to be additive.

What changed#

The methemoglobinemia language is the change. The FDA's 2018 action put a standardized warning on prescription local anesthetics and a Drug Facts warning on over-the-counter oral benzocaine, along with a contraindication against teething use and use under 2 years, and that is why the HurriCaine panel and the Cetacaine insert now read the way they do. That action is covered separately in this directory at the entry fda-benzocaine-teething-warning-2018.

Nothing changed in the dose numbers. Cetacaine's one-second spray and two-second contraindication, and Oraqix's five cartridges, are the same figures those labels have carried.

Where the source is#

Everything above comes from labeling read on DailyMed for this entry. The link under the title opens the Oraqix label; the downloads open Cetacaine Spray and Liquid, Cetacaine Gel, HurriCaine benzocaine 20% gel and the compounded lidocaine 15% ointment record. The FDA's May 2018 benzocaine action, with its archived source documents, is carried in this directory's entry at slug fda-benzocaine-teething-warning-2018. Versions read: Oraqix published April 22, 2026; Cetacaine Spray and Liquid published January 16, 2025; Cetacaine Gel published January 19, 2022; HurriCaine gel published March 16, 2026; the compounded Sincerus Florida ointment published May 17, 2019. DailyMed is free and shows a version history for each record, including the marketing category that identifies an unapproved product. The FDA's own pages on compounded topical anesthetics refused automated access in this session and are not quoted; if your protocol needs them, open fda.gov in a browser.